nafamostat has been researched along with Ischemic Attack, Transient in 5 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The preventive effect of the serine protease inhibitor FUT-175 (nafamostat mesilate), a potent inhibitor of the complement system, against vasospasm was evaluated in 34 high risk patients with thick and diffuse subarachnoid hemorrhage (SAH) demonstrated by computed tomography corresponding to Fisher group 3." | 5.08 | Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. ( Kaminogo, M; Onizuka, M; Shibata, S; Yasunaga, A; Yonekura, M, 1998) |
| "During subarachnoid hemorrhage (SAH), coagulated blood in the subarachnoid space may be regarded as foreign by the immune system." | 1.29 | Cerebral vasospasm caused by cisternal injection of polystyrene latex beads in rabbits is inhibited by a serine protease inhibitor. ( Kikuchi, H; Nozaki, K; Okamoto, S; Yanamoto, H, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yanamoto, H | 4 |
| Kikuchi, H | 4 |
| Okamoto, S | 4 |
| Nozaki, K | 2 |
| Kaminogo, M | 1 |
| Yonekura, M | 1 |
| Onizuka, M | 1 |
| Yasunaga, A | 1 |
| Shibata, S | 1 |
| Sato, M | 1 |
| Shimizu, Y | 1 |
| Yoneda, S | 1 |
2 trials available for nafamostat and Ischemic Attack, Transient
| Article | Year |
|---|---|
Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage.
Topics: Aged; Aneurysm, Ruptured; Benzamidines; Brain Damage, Chronic; Brain Ischemia; Drug Evaluation; Drug | 1998 |
Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cerebral Angiogra | 1992 |
3 other studies available for nafamostat and Ischemic Attack, Transient
| Article | Year |
|---|---|
Cerebral vasospasm caused by cisternal injection of polystyrene latex beads in rabbits is inhibited by a serine protease inhibitor.
Topics: Animals; Benzamidines; Cerebral Angiography; Cisterna Magna; Guanidines; Injections; Ischemic Attack | 1994 |
Effects of protease inhibitor and immunosuppressant on cerebral vasospasm after subarachnoid hemorrhage in rabbits.
Topics: Animals; Benzamidines; Betamethasone; Cyclosporine; Drug Administration Schedule; Gabexate; Guanidin | 1994 |
Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits.
Topics: Animals; Benzamidines; Cerebral Angiography; Cerebral Arteries; Complement Activation; Drug Evaluati | 1992 |